


Supplemental figure 1. Lack of differential monocyte activation in routine and delayed BCG-vaccinated HIV-exposed infants at eight weeks of age. Representative flow plot depicting CD14⁺ and CD16⁺ monocytes of HLA-DR+SSC^{mid}CD3⁻CD20⁻ PBMC (A). Graph depicting the overall monocyte phenotypic distribution in routine (open circles; N=26) or delayed (shaded squares; N=25) BCG-vaccinated infants at 8 weeks of age (B). Only infants in the 'routine' arm had received vaccination at this point while the 'delayed' arm was unvaccinated. Lines depict the median of each group. (C). Plasma concentration of sCD163 in 8-week old infants that received either routine or delayed BCG vaccination. Lines depict the median of each group while the whiskers depict the interquartile ranges. Statistics were performed using a Mann-Whitney test for non-parametric data.



Supplemental Figure 2. Plasma cytokine concentrations in 2 and 6 week old HIV-exposed infants randomized to receive routine or delayed BCG vaccination. Levels of IFN- γ TNF- α , IL-8, IFN- α 2, IP-10 (CXCL10), MCP1 (CCL2), MIP-1 α (CCL4), and GMCSF were assessed in 2-week (A; N=27 for routine and N=31 for delayed) or 6-week (B; N=31 for both groups) infants following routine or delayed BCG vaccination. Only infants in the 'routine' arm received vaccination at these points while the 'delayed' arm was unvaccinated. All values are log₁₀ transformed. Lines depict the mean of each group, and the whiskers represent the standard deviation. Statistics were performed using a two-tailed student's t-test.

Gene Symbol	Assay ID
ARG1	Hs00968979_m1
CCL2	Hs00234140_m1
CCL5	Hs00174575_m1
CCR2	Hs00704702_s1
CD14	Hs02621496_s1
CD209 (DC-SIGN)	Hs01588349_m1
CD86	Hs01567026_m1
CD8A	Hs00233520_m1
CIITA	Hs00172094_m1
CLEC4F	Hs00403246_m1
CSF1R	Hs00911250_m1
CX3CR1	Hs01922583_s1
CXCL10	Hs01124252_g1
CXCL13	Hs00757930_m1
CXCL9	Hs00171065_m1
CXCR3	Hs01847760_s1
EMR1	Hs00173562_m1
FCGR3A/B (CD16)	Hs00275547_m1
GAPDH	Hs02758991_g1
HPRT1	Hs02800695_m1
IDO1	Hs00984148_m1
IFNA1	Hs00855471_g1
IFNAR2	Hs01022060_m1
IFNB1	Hs01077958_s1
IFNG	Hs00989291_m1
IL10	Hs00961622_m1
IL12A	Hs01073447_m1
IL12B	Hs01011518_m1
IL12RB1	Hs00538167_m1
IL18	Hs01038788_m1
IL18BP	Hs00271720_m1
IL1A	Hs00174092_m1
IL1B	Hs00174097_m1
IL23A	Hs00900828_g1
IL6	Hs00985639_m1
IRF4	Hs01056533_m1
ITGAM	Hs00355885_m1
ITGAX	Hs00174217_m1

KLF4	Hs00358836_m1
MARCO	Hs00198935_m1
NOS2	Hs01075529_m1
PTGS2	Hs00153133_m1
SOCS2	Hs00919620_m1
SOCS3	Hs02330328_s1
TNF	Hs01113624_g1
TNFSF9	Hs00169409_m1
TNFSF10 (TRAIL)	Hs00921974_m1

Supplemental Table 1: List of Applied Biosystems TaqMan primer-probe assays used in the study.

Adverse Events	Routine (N=78)	Delayed (N=71)	p-value
Serious Adverse Events	9	3	0.14
Death	3	0	
HIV infection	4	1	
Bacterial meningitis	1	1	
Pneumonia	1	1	
Upper respiratory tract	14	6	0.10
Any symptoms	1	0	
Runny nose	2	2	
Blocked nostrils	11	4	
Lower respiratory tract	15	15	0.84
Cough	15	9	
Chest infection	0	3	
Wheeze	0	3	
Constitutional	6	7	0.77
Fever	6	6	
Jaundice	0	1	
Dermatological	21	21	0.86
Eczema	0	2	
Rash (other)	10	9	
Rash (diaper)	5	7	
Pustules on body	2	2	
Ringworm	2	0	
Erythema	0	1	
Irritated/dry skin	2	0	
Abdominal	5	7	0.55
Vomiting	1	1	
Loose stools	1	3	
Constipation	3	2	
Blood in stool	0	1	
Ear, eye, nose, and throat	6	4	0.75
Coated tongue	1	2	
Oral thrush	3	1	
Eye infection	1	1	
Blocked tear duct	1	0	
Other	3	3	1.00
Swollen scrotum	0	1	
Abscess (face)	0	1	
Splenomegaly	1	1	
Influenza	1	0	
Non-use of right arm	1	0	
TOTAL	79	66	

Supplemental Table 2: Adverse events by randomization arm.